Evidence map›Paper›PMID 37464432›Full record

ArticleAddiction science & clinical practice2023

Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study.

Maximilian Meyer, Ferdinand Gygli, Jean N Westenberg, Otto Schmid, Johannes Strasser, Undine E Lang, Kenneth M Dürsteler, Marc Vogel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction science & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Maximilian Meyer *University of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland. maximilian.meyer@upk.ch.ORCID 0000-0003-1183-1195
Ferdinand Gygli *University of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
Jean N WestenbergUniversity of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
Otto SchmidUniversity of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
Johannes StrasserUniversity of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
Undine E LangUniversity of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
Kenneth M DürstelerUniversity of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
Marc VogelUniversity of Basel Psychiatric Clinics, University of Basel, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
University of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUse of benzodiazepines (BZD) in patients receiving opioid agonist treatment (OAT) is common and associated with a variety of negative health and social outcomes. This cross-sectional study investigates the impact of BZD use in OAT patients on their quality of life (QoL).

methodsA convenience sample of patients receiving oral OAT or heroin-assisted treatment in two outpatient centres in Basel, Switzerland was investigated. Participants (n = 141) completed self-report questionnaires on psychiatric symptoms and psychological distress (The Symptom Checklist 27, SCL-27), depressive state (German version of the Center for Epidemiological Studies Depression Scale), quality of life (Lancashire Quality of Life Profile, LQOLP) and use of BZD and other drugs (self-report questionnaire). Substance use was assessed by urine toxicology testing.

resultsIn bivariate analysis, total QoL scores were significantly lower for lifetime, current, and prolonged BZD users compared to participants without the respective use patterns. There was no significant relationship between BZD dose and QoL. In multivariable linear regression models controlling for psychiatric symptom load and depressive state, only lifetime use predicted lower QoL, whereas other BZD use patterns were not significantly associated.

conclusionsThe association of lower QoL and BZD use in OAT patients is strongly confounded by co-occurring depressive state and psychiatric symptoms. Careful diagnosis and treatment of co-occurring mental disorders in OAT is paramount to improve QoL in this patient population and may also help reduce BZD use.

Indexed as

BenzodiazepinesSubstance-Related DisordersAnalgesics, OpioidCross-Sectional StudiesHumansQuality of LifeAnalgesics, OpioidBenzodiazepinesHeroin-assisted treatmentMethadone maintenance treatmentOpioid use disorderQuality of lifeSedativeSubstitution treatment

Identifiers

PMID37464432
PMCPMC10354905
OpenAlexW4384664027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.